Journey Medical Corporation (NASDAQ: DERM) presented efficacy data from combined Phase 3 clinical trials of its rosacea treatment Emrosi at ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE